MedTrace Logo

Opioid-free Anesthesia in Thyroidectomies

NCT05243940 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-26

No results posted yet for this study

Summary

The aim of this study will be to investigate the effect of an opioid-free anesthesia regimen with a mixture of dexmedetomidine-lidocaine-ketamine in the same syringe versus fentanyl analgesia in elective thyroidectomies. Recovery parameters and nociception levels throughout the operation will be evaluated

Conditions

  • Pain, Post Operative
  • Pain, Acute
  • Pain, Chronic
  • Pain, Neuropathic
  • Pain, Nociceptive
  • Ketamine
  • Dexmedetomidine
  • Lidocaine
  • Fentanyl
  • Analgesia
  • Analgesics
  • Analgesics Non-narcotic

Interventions

DRUG

dexmedetomidine-ketamine-lidocaine (DKL)

patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.

DRUG

remifentanil infusion

remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration

Sponsors & Collaborators

  • Aretaieion University Hospital

    lead OTHER

Principal Investigators

  • KASSIANI THEODORAKI, MD, PhD, DESA · Aretaieion University Hospital, National and Kapodistrian University of Athens, Greece

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-07
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05243940 on ClinicalTrials.gov